Maximizing the Impact of Hematology Analytics and Insights Teams

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Consulting; Research; Health Care; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
AstraZeneca; Bayer; Biotest AG; Decode Consulting; Janssen; Lonza Inc.; MEDiSTRAVA; Momenta; Novartis; Sanofi; Takeda Pharmaceuticals; Vertex Pharmaceuticals

Study Snapshot

Best Practices, LLC engaged 12 Analytics & Insights leaders across 12 leading biopharma organizations with a focus on the hematology segment. This report includes segmentation by company size (mid vs. large pharma) and features deep-dive interviews for added qualitative insights. Notably, over 33% of benchmark participants serve at the director-level or above.

Key topics covered in this report include:

• Core responsibilities and clients supported by Hematology A&I teams
• Valuable strategic practices, skill sets, and expertise areas
• High-value analytics, methodologies, platforms and outsourcing approaches
• Streamlining market research via advanced analytics
• Internal branding programs
• Innovation centers of excellence: Usage, staffing, services and alignment
• Top A&I obstacles, mistakes and lessons
• Innovative pilots, design thinking and patient engagement

• Highest Strategic Value for A&I Teams May Come Through Less-Routine Activities: 85-95% of benchmarked hematology A&I teams routinely provide insights-based recommendations, interpret insights, and leverage experience to be effective advisors. Best-in-class teams may be bolder, recommending specific business action with implementation plans, focusing on business risks or incubating genuine innovation, thereby providing evidence-based success stories for other groups (such as Medical Affairs) to demonstrate their value internally. A&I teams in smaller organizations more routinely execute these tactics.

• Growing Prevalence of CoEs Among Mid-Sized and Large Pharma: 30% of surveyed hematology companies have established a designated Innovation Center of Excellence (CoE), - with plans to add these CoEs in the next 1-2 years - while most do not have an Excellence team yet.

• Time allocation of Hematology A&I teams across key internal functions – Total benchmark class
• Comparison of Hematology A&I support across key internal functions – Large pharma vs. mid-pharma
• Voices from the field: Building holistic view for improving business results
• Role played by Hematology Analytics & Insights groups in fulfilling the listed organizational capabilities
• Role played by Analytics & Insights groups in fulfilling the listed organizational capabilities – Large pharma vs. mid-pharma

• Strategic initiatives used by Hematology A&I teams to enhance stakeholder impact
• Voices from the field: Making consensual and collaborative plans and recommendations to clients
• Effective practices used by Analytics & Insights groups to provide greater value to stakeholders – Large pharma vs. mid-pharma
• Soft skills and prior experiences essential for Hematology A&I professionals
• Interview narratives around staffing an analytics organization
• Soft skills and prior experiences essential for Hematology A&I professionals – Large pharma vs. mid-pharma
• Most critical technical skills for Hematology A&I professionals
• Most critical technical skills for Hematology A&I professionals – Large pharma vs. mid-pharma
• Top obstacles to the future success of the Hematology Analytics & Insights function
• Interview narratives around what can drive the approach to analytics capabilities
• Interview narrative around analytics and different therapeutic areas
• Top obstacles to the future success of the Hematology Analytics & Insights function – Large pharma vs. mid-pharma
• Pitfalls and common missteps in Hematology A&I strategy execution
• Methods to foster continuous innovation across Hematology A&I

• Analytic methodologies used by Hematology Analytics & Insights groups for different operational purposes
• Analytic methodologies applied by Hematology A&I for diverse use cases – Strategic A&I teams vs. total benchmark class
• Interview narrative around determining “Next Best Action” in promotional mix
• Analytic methodologies used by A&I groups for various operational purposes – Large pharma vs. mid-pharma
• Interview narrative around predictive analytics in R&D
• High-impact analytics projects supporting brand, HEOR, and other key internal partner teams – Total benchmark class
• High-value analytics projects supporting brand, HEOR, and other key internal partner teams – Strategic A&I teams
• Interview narratives around the outputs from new analytics platforms
• Interview narratives around data mining and usage with digitization
• Valuable analytics projects for informing brand, HEOR and other key internal partner teams and driving measurable results in the market – Large pharma vs. mid-pharma
• Interview narrative around characterizing the activities that are enabling to connect the dots, in terms of analytic operations and methodologies performed
• Insource vs. outsource approach for hematology analytics projects – Total benchmark class
• Interview narrative around benefits of insourcing analytics
• Insource vs. outsource approach for hematology analytics projects – Large pharma vs. mid-pharma
• Insource vs. outsource approach for specific methodologies and processes
• Insource vs. outsource approach for specific methodologies and processes – Large pharma vs. mid-pharma
• Market research substitution with analytics in hematology
• Interview narratives around opportunities for more boutique research methodologies
• Interview narratives around approaches that tend to stifle innovation
• Use of analytics to replace market research – Large pharma vs. mid-pharma
• Most utilized analytics and reporting platforms
• Benchmark peer assessments (pros and cons) of leading analytics platforms
• Interview narrative around an ideal analytics platform in hematology

• Internal branding campaign rollout to shape perception of the Hematology A&I function
• Key goals behind internal branding in Hematology Analytics & Insights functions – Total benchmark class
• Structural challenges, different data sources, and interview narrative around Analytics & Insights from medical perspective
• Vendor support for internal branding efforts
• Interview narratives around measurement and overall impact of formal branding efforts

• Adoption of innovation CoEs to scale expertise and transformation – Total benchmark class
• Interview narrative around digital solutions by innovation centers of excellence
• Adoption of innovation CoE to leverage expertise and drive new improvements – Large pharma vs. mid-pharma
• Relationship between innovation CoE (or similar department) and Analytics & Insights groups – Total benchmark class and Large pharma vs. mid-pharma
• Number of FTEs working in hematology-focused innovation CoEs or similar departments
• Effective services delivered by innovation CoE (or similar groups) in supporting the overall organization
• Critical background and skills required for staff working in an innovation CoE or similar department

• Use of a formal design thinking methodology in performance and innovation efforts
• Direct patient engagement initiatives to understand real-world hematology needs
• Disease areas in which benchmark organizations have made a positive impact using patient engagement programs to better meet patient needs – Primary care, specialty, and rare diseases
• Disease areas in which benchmark organizations have made a positive impact using patient engagement programs to better meet patient needs – By drug routes and drug types